# NPC - AXEL Study : Axitinib-Avelumab

> **NCT04562441** · PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 13 (actual)

## Conditions studied

- Recurrent or Metastatic NPC

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04562441
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-06
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-11-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562441, "NPC - AXEL Study : Axitinib-Avelumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04562441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*